BNTX Q4 2025 Earnings
Reported Mar 10, 2026 at 6:53 AM ET · SEC Source
Q4 25 EPS
$-1.25
MISS 405.66%
Est. $-0.25
Q4 25 Revenue
$907.4M
BEAT +24.34%
Est. $729.8M
vs S&P Since Q4 25
+14.6%
BEATING MARKET
BNTX +21.0% vs S&P +6.4%
Full Year 2025 Results
FY 25 EPS
$-4.70
MISS 36.62%
Est. $-3.44
FY 25 Revenue
$2.87B
BEAT +6.60%
Est. $2.69B
Market Reaction
Did BNTX Beat Earnings? Q4 2025 Results
BioNTech delivered a deeply split fourth quarter, posting revenue that cleared Wall Street expectations while its bottom line fell far short of what analysts had anticipated. The German biotech reported Q4 2025 revenue of $907.40 million, beating the… Read more BioNTech delivered a deeply split fourth quarter, posting revenue that cleared Wall Street expectations while its bottom line fell far short of what analysts had anticipated. The German biotech reported Q4 2025 revenue of $907.40 million, beating the $729.77 million consensus by 24.34%, yet revenue still declined 23.8% year over year as waning COVID-19 vaccine demand continued to erode the company's top line. The earnings picture was considerably darker, with an EPS loss of $1.25 against a consensus estimate of $-0.25, a miss of 405.66%, driven in large part by elevated other operating expenses tied to contractual dispute settlements and pipeline prioritization costs. Compounding the financial narrative, co-founders Ugur Sahin and Özlem Türeci announced plans to depart by end of 2026 to establish an independent mRNA-focused venture, triggering a sharp sell-off in shares. Looking ahead, BioNTech guided 2026 revenues of €2,000 to €2,300 million, while six late-stage oncology data readouts and eight planned Phase 3 trials for pumitamig offer investors a pipeline-driven thesis as the COVID era recedes.
Key Takeaways
- • Q4 revenue decline driven by lower COVID-19 vaccine sales due to reduced market demand
- • Full year revenue increase driven by BMS collaboration revenues recognized in Q3 2025
- • R&D expense decreases from active portfolio management and pumitamig cost sharing with BMS
- • SG&A increases driven by ongoing commercial build-up for oncology launches
- • Other operating expenses elevated by settlements of contractual disputes, pipeline prioritization costs, and FX differences
BNTX YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
BNTX Revenue by Segment
Business unit performance breakdown
“2025 was a year of strong execution and pipeline momentum, marked by substantial progress in delivering on our strategy. We advanced our oncology pipeline by moving multiple programs into late-stage development and initiated trials assessing novel-novel combination approaches with the aim of delivering differentiated therapeutic profiles.”
— Ugur Sahin, Q4 2025 Earnings Press Release
BNTX Earnings Trends
BNTX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BNTX EPS Trend
Earnings per share: estimate vs actual
BNTX Revenue Trend
Quarterly revenue: estimate vs actual
BNTX Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | $-2.14 | — | — | — | — |
| Q4 25 MISS FY | $-0.25 | $-1.25 | -405.66% | $907.4M | +24.34% |
| FY Full Year | $-3.44 | $-4.70 | -36.62% | $2.87B | +6.60% |
| Q3 25 MISS | $0.10 | $-0.12 | -220.36% | — | — |
| Q2 25 MISS | $-1.41 | $-1.85 | -31.65% | $301.6M | +14.39% |